Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
19 déc. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Biora's latest patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tract.
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
18 déc. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Transaction results in nearly 60% reduction in net debt and brings $16 million in new capital; demonstrates investor confidence in near-term catalysts.
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
11 déc. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Pharma collaborator’s proprietary molecules will be tested with the BioJet platform in animal models.
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
30 nov. 2023 16h48 HE
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
13 nov. 2023 16h05 HE
|
Biora Therapeutics, Inc.
NaviCap™ platform advancing toward initiation of phase 1 clinical trial by year end; Pharma collaborations accelerate for the BioJet™ platform
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
06 nov. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST
Biora Therapeutics Submits Updated IND Application for BT-600
30 oct. 2023 16h05 HE
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Biora Therapeutics to Submit Updated IND Application for BT-600
23 oct. 2023 17h30 HE
|
Biora Therapeutics, Inc.
Update to include supplemental information and allow additional time for regulatory review. Biora anticipates remaining on track with ph1 trial timeline.
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
05 oct. 2023 08h00 HE
|
Biora Therapeutics, Inc.
Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
25 sept. 2023 08h00 HE
|
Biora Therapeutics, Inc.
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust...